Kalaris Therapeutics (KLRS) Tops Q2 EPS by 2c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.48), $0.02 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• Nucor projects Q3 2026 earnings above prior year, below estimates
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• Morgan Stanley Downgrades Orange SA (ORA:FP) (ORAN) to Underweight